ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 0102

Iron Metabolism Dysregulation and Inflammation in Ankylosing Spondylitis: Role of SLC39A14 in Extracellular Matrix Remodeling
Abstract Number: 0103

Common and Rare Variant Contributions to Familial Aggregation in Spondyloarthritis
Abstract Number: 0104

Dissecting the Genetic and Functional Association of CARD9 with Axial Spondyloarthritis
Abstract Number: 0105

Inflammatory Cytokines, Matrix Metalloproteinases and Bone Markers Expressions Are Modulated in the Joints in the Chronic Murine Model of Imiquimod-Induced Psoriasis
Abstract Number: 0106

Investigation of DNA Methylation Inhibition in a Mouse Model of Ankylosing Spondylitis
Abstract Number: 0107

Role of Achilles Elastography in Differentiating Patients with Early Psoriatic Arthritis
Abstract Number: 0108

In Vivo and In Vitro Analysis of IL-23 Modulation Following Anti-TNF Therapy in Psoriatic Arthritis
Abstract Number: 0109

Application of Psoriatic Arthritis Mouse Models in Preclinical Pharmacodynamic Evaluation
Abstract Number: 0110

SKG Mice Develop CD4⁺ T Cell–Driven Psoriasis and Enable Study of Endogenous Antigen-Specific Responses
Abstract Number: 0111

Predicting Response To Adalimumab In Patients With Psoriatic Arthritis Using Epigenetic Chromosome Conformation Signatures
Abstract Number: 0112

Proteome-wide Mendelian Randomization Identifies Therapeutic Targets in Psoriatic Arthritis
Abstract Number: 0113

ZEB2 and MLCK1 may impair gut barrier integrity in MIF-Deficient SKG Mice
Abstract Number: 0114

A rare variant in the Extl3 gene is associated with altered Wnt signaling pathway in a novel mouse model of axial spondyloarthritis
Abstract Number: 0115

Dysfunctional Mitophagy Propels Neutrophil Hyperactivity and Thrombosis in Antiphospholipid Syndrome
Abstract Number: 0116

Cerebral small vessel disease in antiphospholipid syndrome: subtypes and total burden of cSVD on MRI

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].